Merck to Acquire Idenix

Acquisition Expands Portfolio of Promising Investigational Therapies for Hepatitis C WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass., June 9, 2014–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), today announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 […]